XORTX Net Tangible Assets vs Total Current Liabilities Analysis

XRTX Stock

1.73 0.15 7.98%

XORTX Therapeutics financial indicator trend analysis is more than just analyzing XORTX Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether XORTX Therapeutics is a good investment. Please check the relationship between XORTX Therapeutics Net Tangible Assets and its Total Current Liabilities accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.

Net Tangible Assets vs Total Current Liabilities

Net Tangible Assets vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of XORTX Therapeutics Net Tangible Assets account and Total Current Liabilities. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between XORTX Therapeutics' Net Tangible Assets and Total Current Liabilities is -0.37. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of XORTX Therapeutics, assuming nothing else is changed. The correlation between historical values of XORTX Therapeutics' Net Tangible Assets and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of XORTX Therapeutics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Net Tangible Assets i.e., XORTX Therapeutics' Net Tangible Assets and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

-0.37

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Total Current Liabilities

Total Current Liabilities is an item on XORTX Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of XORTX Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from XORTX Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into XORTX Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XORTX Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.Selling General Administrative is likely to drop to about 1.8 M in 2024. Issuance Of Capital Stock is expected to grow at the current pace this year

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	17.9K	55.5K	139.7K	146.7K
Total Operating Expenses	3.6M	9.9M	6.0M	4.1M

Reconciled Depreciation Total Operating Expenses

XORTX Therapeutics fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Other Stockholder Equity	Deferred Long Term Liab	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Cash	Non Current Assets Total	Long Term Debt	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital	Intangible Assets	Property Plant And Equipment Net
Other Current Liab		-0.35	0.87	-0.89	0.15	0.73	0.78	0.89	-0.61	0.71	0.93	1.0	0.7	0.7	0.66	0.8	-0.61	-0.11	0.57	0.56	0.47	0.7	0.88	0.73	-0.92	0.55
Total Current Liabilities	-0.35		-0.37	0.19	0.83	-0.19	-0.02	-0.36	0.69	0.02	-0.37	-0.35	-0.11	-0.22	-0.08	-0.21	0.69	-0.08	0.2	-0.23	0.38	-0.22	-0.31	-0.08	0.31	0.41
Net Tangible Assets	0.87	-0.37		-0.81	0.15	0.66	0.8	0.92	-0.53	0.89	0.94	0.87	0.91	0.92	0.9	0.97	-0.53	0.11	0.79	0.13	0.67	0.92	0.98	0.92	-0.75	0.49
Retained Earnings	-0.89	0.19	-0.81		-0.36	-0.79	-0.93	-0.94	0.63	-0.65	-0.96	-0.89	-0.6	-0.57	-0.58	-0.79	0.63	0.41	-0.54	-0.3	-0.47	-0.57	-0.82	-0.64	0.96	-0.77
Accounts Payable	0.15	0.83	0.15	-0.36		0.22	0.53	0.21	0.31	0.44	0.19	0.15	0.3	0.18	0.32	0.3	0.31	-0.25	0.56	-0.16	0.69	0.18	0.2	0.35	-0.21	0.82
Other Assets	0.73	-0.19	0.66	-0.79	0.22		0.76	0.64	-0.31	0.58	0.77	0.73	0.53	0.52	0.5	0.61	-0.31	-0.02	0.47	0.42	0.43	0.52	0.67	0.54	-0.69	0.41
Net Receivables	0.78	-0.02	0.8	-0.93	0.53	0.76		0.87	-0.39	0.74	0.88	0.78	0.68	0.64	0.67	0.85	-0.39	-0.3	0.7	0.07	0.65	0.64	0.83	0.73	-0.83	0.83
Other Stockholder Equity	0.89	-0.36	0.92	-0.94	0.21	0.64	0.87		-0.73	0.72	0.98	0.89	0.71	0.71	0.69	0.89	-0.73	-0.3	0.6	0.17	0.48	0.7	0.9	0.74	-0.92	0.67
Deferred Long Term Liab	-0.61	0.69	-0.53	0.63	0.31	-0.31	-0.39	-0.73		-0.16	-0.68	-0.61	-0.2	-0.22	-0.18	-0.38	1.0	0.48	0.04	-0.27	0.18	-0.22	-0.44	-0.21	0.72	-0.24
Total Current Assets	0.71	0.02	0.89	-0.65	0.44	0.58	0.74	0.72	-0.16		0.76	0.71	0.99	0.96	0.99	0.92	-0.16	0.31	0.97	0.03	0.92	0.96	0.89	0.99	-0.52	0.55
Common Stock	0.93	-0.37	0.94	-0.96	0.19	0.77	0.88	0.98	-0.68	0.76		0.93	0.75	0.74	0.72	0.89	-0.68	-0.19	0.62	0.27	0.51	0.74	0.92	0.77	-0.92	0.62
Property Plant Equipment	1.0	-0.35	0.87	-0.89	0.15	0.73	0.78	0.89	-0.61	0.71	0.93		0.7	0.7	0.66	0.8	-0.61	-0.11	0.57	0.56	0.47	0.7	0.88	0.73	-0.92	0.55
Total Assets	0.7	-0.11	0.91	-0.6	0.3	0.53	0.68	0.71	-0.2	0.99	0.75	0.7		0.99	1.0	0.92	-0.2	0.39	0.95	0.01	0.87	0.99	0.9	1.0	-0.48	0.43
Total Stockholder Equity	0.7	-0.22	0.92	-0.57	0.18	0.52	0.64	0.71	-0.22	0.96	0.74	0.7	0.99		0.99	0.92	-0.22	0.44	0.91	0.03	0.82	1.0	0.91	0.98	-0.48	0.34
Cash	0.66	-0.08	0.9	-0.58	0.32	0.5	0.67	0.69	-0.18	0.99	0.72	0.66	1.0	0.99		0.91	-0.18	0.39	0.95	-0.04	0.88	0.99	0.88	0.99	-0.45	0.44
Non Current Assets Total	0.8	-0.21	0.97	-0.79	0.3	0.61	0.85	0.89	-0.38	0.92	0.89	0.8	0.92	0.92	0.91		-0.38	0.08	0.86	-0.02	0.77	0.92	0.98	0.94	-0.71	0.59
Long Term Debt	-0.61	0.69	-0.53	0.63	0.31	-0.31	-0.39	-0.73	1.0	-0.16	-0.68	-0.61	-0.2	-0.22	-0.18	-0.38		0.48	0.04	-0.27	0.18	-0.22	-0.44	-0.21	0.72	-0.24
Common Stock Shares Outstanding	-0.11	-0.08	0.11	0.41	-0.25	-0.02	-0.3	-0.3	0.48	0.31	-0.19	-0.11	0.39	0.44	0.39	0.08	0.48		0.34	0.0	0.33	0.44	0.1	0.32	0.46	-0.55
Non Current Liabilities Total	0.57	0.2	0.79	-0.54	0.56	0.47	0.7	0.6	0.04	0.97	0.62	0.57	0.95	0.91	0.95	0.86	0.04	0.34		-0.11	0.98	0.91	0.8	0.95	-0.39	0.57
Other Current Assets	0.56	-0.23	0.13	-0.3	-0.16	0.42	0.07	0.17	-0.27	0.03	0.27	0.56	0.01	0.03	-0.04	-0.02	-0.27	0.0	-0.11		-0.12	0.03	0.14	0.03	-0.43	0.0
Total Liab	0.47	0.38	0.67	-0.47	0.69	0.43	0.65	0.48	0.18	0.92	0.51	0.47	0.87	0.82	0.88	0.77	0.18	0.33	0.98	-0.12		0.82	0.69	0.88	-0.3	0.6
Net Invested Capital	0.7	-0.22	0.92	-0.57	0.18	0.52	0.64	0.7	-0.22	0.96	0.74	0.7	0.99	1.0	0.99	0.92	-0.22	0.44	0.91	0.03	0.82		0.91	0.98	-0.47	0.34
Capital Stock	0.88	-0.31	0.98	-0.82	0.2	0.67	0.83	0.9	-0.44	0.89	0.92	0.88	0.9	0.91	0.88	0.98	-0.44	0.1	0.8	0.14	0.69	0.91		0.91	-0.77	0.53
Net Working Capital	0.73	-0.08	0.92	-0.64	0.35	0.54	0.73	0.74	-0.21	0.99	0.77	0.73	1.0	0.98	0.99	0.94	-0.21	0.32	0.95	0.03	0.88	0.98	0.91		-0.53	0.5
Intangible Assets	-0.92	0.31	-0.75	0.96	-0.21	-0.69	-0.83	-0.92	0.72	-0.52	-0.92	-0.92	-0.48	-0.48	-0.45	-0.71	0.72	0.46	-0.39	-0.43	-0.3	-0.47	-0.77	-0.53		-0.68
Property Plant And Equipment Net	0.55	0.41	0.49	-0.77	0.82	0.41	0.83	0.67	-0.24	0.55	0.62	0.55	0.43	0.34	0.44	0.59	-0.24	-0.55	0.57	0.0	0.6	0.34	0.53	0.5	-0.68

Click cells to compare fundamentals

XORTX Therapeutics Account Relationship Matchups

XORTX Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	1.3M	1.0M	701.0K	2.1M	294.9K	280.2K
Net Tangible Assets	(484.1K)	1.0M	16.5M	9.2M	10.6M	11.1M
Retained Earnings	(6.8M)	(8.0M)	(9.7M)	(19.2M)	(17.9M)	(17.0M)
Accounts Payable	607.4K	390.0K	410.7K	1.8M	195.8K	186.0K
Net Receivables	9.0K	11.3K	40.4K	81.8K	60.7K	36.9K
Other Stockholder Equity	683.0K	1.0M	6.4M	8.0M	9.2M	9.7M
Total Current Assets	815.2K	2.1M	20.2M	14.8M	4.1M	6.7M
Total Assets	1.1M	2.3M	22.0M	12.3M	5.5M	8.2M
Total Stockholder Equity	(211.7K)	1.3M	16.7M	7.0M	4.6M	5.4M
Cash	58.6K	171.3K	18.9M	10.4M	3.4M	6.1M
Non Current Assets Total	272.7K	234.3K	1.9M	1.5M	1.4M	1.0M
Total Liab	1.3M	1.0M	5.3M	5.4M	825.9K	784.6K
Net Invested Capital	(160.9K)	1.3M	16.7M	7.0M	4.6M	5.5M
Net Working Capital	(484.5K)	1.0M	14.9M	9.4M	3.8M	5.2M
Intangible Assets	272.4K	234.3K	256.2K	199.4K	175.3K	189.7K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC